INVESTOR PRESENTATION

September 2023

1

Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than

statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates", "believes", "estimates", "expects", "intends", "plans", "predicts", "projects" and similar expressions. Risks and uncertainties that could affect us include, without limitation:

  • General economic and business conditions in India and other key global markets in which we operate;
  • The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
  • Changes in the value of the Rupee and other currency changes;
  • Changes in the Indian and international interest rates;
  • Allocations of funds by the Governments in our key global markets;
  • Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
  • Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
  • Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

For more detailed information on the risks and uncertainties associated with the Company's business activities, please see the company's annual report filed in Form 20-F with the US SEC for the fiscal year ended March 31, 2023 and quarterly financial statements filed in Form 6-K with the US SEC for the quarters ended Jun 30, 2023, Sep 30, 2023, and our other filings with US SEC. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events.

2

|

September 2023

|

Investor Presentation

|

As per consolidated financial statements under IFRS

Dr. Reddy's at a glance

74

countries

53

nationalities

Note: The map is not to scale and is an artistic representation.

We accelerate access to affordable and innovative medicines because

Good Health Can't Wait.

689mn patients reached globally

$2.99bn Revenue

15% Revenue Growth

~30% EBITDA%

21% RoCE

24,832 Employees globally

30 Plants (Manufacturing & R&D)

All information as of FY23

3

|

September 2023

|

Investor Presentation

|

As per consolidated financial statements under IFRS

Our Journey

Early 90s

Expanded internationally

by establishing presence in Russia and the U.S. by the mid-1990

1984

Dr. Anji Reddy established Dr.

Reddy's Laboratories

1st Indian company to initiate new drug

discovery (1993)

2006-07

1st Indian pharma company to launch an Authorized Generic (AG) in the U.S

Became fastest Indian pharma company to cross USD 1 bn in revenue

Launched the world's first monoclonal

antibody biosimilar of rituximab in India

(Reditux)

2010

Launched the world's first and India's only generic of darbepoetin alfa (Cresp)

2015

Acquired portfolio of Belgium- based UCB's established brands in certain South Asian countries

2022-23

Acquired German medical cannabis company, Nimbus - segment-wise,a

1st for an Indian pharma company

1 of 2 Indian pharma cos to be recognised by World Economic Forum as part of its Global Lighthouse Network for Hyderabad facility

2020-21

5+ million patients served during COVID - therapeutics & vaccine

Acquired select divisions of Wockhardt in India

Late 80s

Dr. Reddy's went public (BSE) (1986)

1st Indian company to export APIs to the USA at scale (Late 80s onwards)

1997

Indian pharma company to license a novel drug to an innovator

2001

1st Indian pharma company to obtain 180- day marketing exclusivity from the USFDA (fluoxetine 40mg)

1st pharma company in Asia outside Japan to list on the New York Stock Exchange

2019

Entered the nutraceuticals segment in India (Celevida)

1st Indian pharma company to get approval for supplying generic drugs to China's public hospitals

1st Indian & 3rd Asian company to join

Science-Based targets initiative (SBTi)

1980s 1990s

2000s

2010s

2020s

4

|

September 2023

|

Investor Presentation

|

As per consolidated financial statements under IFRS

OUR STRATEGY

Progressing on our journey by…

STRENGTHENING OUR CORE

Generics

Branded

Generics

API

BiosimilarsOTC

(GROWTH DRIVERS IN SHORT TO MEDIUM TERM)

INVESTING IN INNOVATIVE SPACES

Disease

Management

Immuno-

CDMO

oncology

(small and

NCEs

large mol.)

Nutraceuticals

Biologics

Digital

and CGT

Services

D2C

(GROWTH DRIVERS IN SHORT TO LONG TERM)

6

|

September 2023

|

Investor Presentation

|

As per consolidated financial statements under IFRS

…to deliver on our aspirations

GROWTH

RETURNS

SUSTAINABILITY

Serving 1.5 Bn+ patients

2 5 % E B IT D A and

Be a leader

Double digit revenue

2 5 % R O C E

growth

7

|

September 2023

|

Investor Presentation

|

As per consolidated financial statements under IFRS

Our Approach

LEADERSHIP IN CHOSEN SPACES

With patients at the center, our execution is driven by three pillars of Market Leadership, Productivity and Innovation

  • Focus on 'products that matter'
  • Economy of scale, complex brands and clinically differentiated products

To Serve 1.5Bn+ patients

PRODUCTIVITY

PATIENT FOCUSED INNOVATION

• Digital and automation

• Incremental & breakthrough

• Operational & commercial excellence

• Unmet needs & user delight

• Continuous improvement

• Continue to grow core generics business while

investing in the innovation spaces

8

|

September 2023

|

Investor Presentation

|

As per consolidated financial statements under IFRS

STRATEGY IN ACTION :

BUSINESS OVERVIEW

Global Revenues

North America

For the fiscal year 2023 (Apr'22 to Mar'23)

REVENUE BY SEGMENT

GLOBAL GENERICS REVENUE BY GEOGRAPHY

₹ 10,170 Cr

₹ 1760 Cr

North America

Europe

GLOBAL GENERICS

36%YoY

6%YoY

87%

₹ 24,588 Cr

41%

7%

15%YoY

PSAI

12%

OTHERS

20%

₹ 4,893 Cr

1%

India

17%YoY

₹ 21,377 Cr

₹ 2,907 Cr

Pharmaceutical Services &

Global Generics

Active Ingredients

19%YoY

5%YoY

₹ 4,553 Cr

19%

Emerging Markets

YoY

10 |

September 2023

|

Investor Presentation

|

As per consolidated financial statements under IFRS

Attachments

Disclaimer

Dr. Reddy's Laboratories Limited published this content on 12 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 April 2024 10:01:06 UTC.